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Abstract The large use of target therapies in the treat-
ment of gastrointestinal stromal tumors (GISTs)
highlighted the urgency to integrate new molecular imag-
ing technologies, to develop new criteria for tumor
response evaluation and to reach a more comprehensive
deﬁnition of the molecular target. These aspects, which
come from clinical experiences, are not considered enough
in preclinical research studies which aim to evaluate the
efﬁcacy of new drugs or new combination of drugs with
molecular target. We developed a xenograft animal
model GIST882 using nude mice. We evaluated both the
molecular and functional characterization of the tumor
mass. The mutational analysis of KIT receptor of the
GIST882 cell lines and tumor mass showed a mutation on
exon 13 that was still present after in vivo cell growth. The
glucose metabolism and cell proliferation was evaluated
with a small animal PET using both FDG and FLT. The
experimental development of new therapies for GIST
treatment requires sophisticated animal models in order to
represent the tumor molecular heterogeneity already dem-
onstrated in the clinical setting and in order to evaluate the
efﬁcacy of the treatment also considering the inhibition of
tumor metabolism, and not only considering the change in
size of tumors. This approach of cancer research on GISTs
is crucial and essential for innovative perspectives that
could cross over to other types of cancer.
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Introduction
In the era of molecular target therapies for cancer, some
relevant and novel aspects from the clinical setting should
be considered for the in vivo experimental studies aimed at
the development of new therapeutic strategies. The need to
deﬁne the molecular target and the new concepts on
response assessment to treatment are the two most impor-
tant ones. An example is demonstrated with gastrointestinal
stromal tumors (GISTs). In fact, in the last few years for
the ﬁrst time clinical experiences on GISTs patients high-
lighted both these aspects. GISTs are characterized by
oncogenic mutations of KIT or platelet-derived growth
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DOI 10.1007/s10238-009-0033-5factor receptor (PDGFr)-alfa resulting in a constitutive
activation of their downstream signalling which principally
includes the control of cell proliferation [1, 2]. Agents such
as imatinib and sunitinib, tyrosine kinase (TK) inhibitors
speciﬁcally directed against KIT and PDGFr-alfa receptors,
dramatically changed the natural course of the disease of
patients affected by metastatic or inoperable GIST and lead
to the possibility to treat cancer with target therapies [3, 4].
Moreover, the tumor response cannot be still evaluated
only using the traditional response evaluation criteria in
solid tumors (RECIST) [5, 6]. Notwithstanding that both
these advances are well considered in the clinical setting of
medical oncology, they are still lacking in most of the
experimental studies. The preclinical development of new
drugs or combination of drugs with molecular targets
should be planned with a modern approach based ﬁrstly on
the use of advanced animal models.
The aim of this study is the development of a xenograft
GIST animal model including molecular analyses for both
target and molecular imaging technologies such as small
animal positron emission tomography (PET) for tumor
metabolism evaluation.
Materials and methods
Cells
The human GIST cell line GIST882 was kindly provided
by Dr. Jonathan A. Fletcher, Harvard Medical School,
Boston, Massachusetts, USA. Cells were routinely cultured
in RPMI 1640 supplemented with 15% fetal bovine serum
and were maintained at 37C in a humidiﬁed 5% CO2
atmosphere. All medium constituents were purchased from
Invitrogen, Milan, Italy.
Cytoﬂuorometric studies
GIST882 phenotype was studied by means of indirect
immunoﬂuorescence and cytoﬂuorometric analysis. The
following primary mouse monoclonal antibodies were
used: anti- human KIT clone YB5.B8 (Pharmingen, San
Diego, CA); anti- human HER-1 (EGF-R) clone 528
(Oncogene Research Products, Uniondale, NY); anti-
human HER-2 clone MGR-3; anti- human HER-3 clone
SGP1 (NeoMarkers, Fremont, CA); anti- human IGF-IR
clone aIR3 (Calbiochem). The secondary antibody was
Alexa Fluor 488 F(ab’)2 fragment of goat anti-mouse IgG
(Invitrogen, Milan, Italy). After the ﬁnal washings, cells
were resuspended in phosphate-buffered saline containing
1 lg/ml of ethidium bromide to gate out dead cells and
were subjected to cytoﬂuorometric analysis with a FAC-
Scan (Becton Dickinson, St. Jose, CA).
KIT and PDGFRA mutational analysis
in GIST882 cells
Genomic DNA was isolated from GIST882 cells using
Blood & Cell Culture DNA Midi Kit (Qiagen, Valencia,
CA), according to manufacturer’s instructions. KIT
exons 9, 11, 13, and 17 and PDGFRA exons 12 and 18
were ampliﬁed by PCR and screened for mutations
by denaturing high-performance liquid chromatography
(DHPLC, Wave, Transgenomic, Omaha, NE). DNA
sequencing of the mutated c-KIT or PDGFRA was done
for exons with a mutated proﬁle at DHPLC using CEQ
TM
8000 Genetic Analysis System (Beckman Coulter, Ful-
lerton, CA).
Mice
Athymic Crl:CD-1-Foxn1
nu/nu mice (referred to as nude
mice) were purchased from Charles River Italy and
kept under sterile conditions. Experiments were autho-
rized by the institutional review board of the University of
Bologna and done according to Italian and European
guidelines.
To study tumorigenicity GIST882 cells (3 9 10
6 and
30 9 10
6) were injected subcutaneously (s.c.) in the right
hind leg or intra peritoneum (i.p.). Tumor incidence and
growth were evaluated weekly. Neoplastic masses were
measured with calipers; tumor volume was calculated as
p[H(ab)]
3/6, where a = maximal tumor diameter and
b = tumor diameter perpendicular to a. At sacriﬁce sam-
ples of the tumor mass were ﬁxed in 10% phosphate-
buffered formalin or fronzen in liquid nitrogen.
In vivo imaging studies
Imaging studies were performed using small animal PET
tomograph (GE, eXplore Vista DR). Animals did PET
scans after gas anaesthesia (Sevoﬂuorane 3–5% and oxy-
gen 1 l/min). The detection of a GIST tumor mass and the
study tumor metabolism and proliferation were performed
using two tracers: 18-ﬂuoro-deoxiglucose (FDG) for glu-
cose metabolism and 18-ﬂuoro-deoxythymidine (FLT) for
cell proliferation. FLT studies were performed 4 days after
FDG acquisition.
Tumor biological studies
Histological evaluation and KIT immunohistochemical
(IHC) analysis were performed in order to conﬁrm the
GIST diagnosis. The mutational analysis of KIT receptor
was performed again in order to conﬁrm that the muta-
tional characteristic was still present after in vivo cell
growth.
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By means of indirect immunoﬂuorescence and cytoﬂu-
orometric analysis we studied the growth factor receptor
expression proﬁle of GIST882 cells including expression
analysis of KIT, some HER/erbB family receptors and
IGF-IR. As indicated by the cytoﬂuorometric proﬁle
GIST882 cells expressed KIT as well as HER-1 (EGF-R)
and HER-2 proteins (Fig. 1). Surface expression of HER-3
proteins and IGF-I R were not detectable. The expression
of other growth factor receptors and TKs suggests that
additional target therapies could be combined to KIT target
therapy in GIST tumors and could be preclinically evalu-
ated in this tumor model.
The mutational analysis, as expected, showed a mutation
on KIT receptor exon 13 (homozygous mutation—K642E)
(Fig. 2).
The xenograft tumor model was established by s.c. or.
i.p. injection of GIST882 cells into nude mice. No tumor
growth was seen after i.p. injection. After subcutaneos
injection, growth of tumor became evident after a median
latency time of 41 days in the case of injection of 3 9 10
6
cells and 25 days in the case of injection of 30 9 10
6 cells.
The percentage of tumor uptake was 80% (4 tumor bearing
animals out of 5) at the dose of 3 9 10
6 cells and 67% (2
tumor bearing animals out of 3) at the dose of 30 9 10
6.
Tumor growth was very slow and sometimes indolent as
shown by the in vivo growth curve (Fig. 3). In the group
that received 3 9 10
6 cells 2 animals did not show any
progressive growth.
PET analysis was performed at 88 days in the 3 9 10
6
treated group. The FDG and FLT was well uptaken in all
tumor mass (Fig. 4). Histological evaluation and KIT
(IHC) analysis conﬁrmed the GIST diagnosis (Fig. 5).
Mutational analysis of tumor samples showed again the
mutation on KIT receptor exon 13 (Fig. 2).
Discussion
In the last years, the large use of target therapies in the
treatment of cancer highlighted the urgency to use new
imaging technologies, to develop new criteria for tumor
response evaluation and to reach a more comprehensive
deﬁnition of the molecular target. The experimental studies
aimed to the development of new drugs for cancer treat-
ment should consider all these aspects.
Fig. 1 Cytoﬂuorometric analysis of c-kit, HER-1, HER-2, HER-3
and IGF-IR expression in GIST882 cells. Open proﬁle represents cells
stained with secondary antibody alone; solid proﬁle represents cells
stained with the speciﬁc primary antibody. In each panel the ordinate
represents the number of cells. Data from an experiment represen-
tative of at least two similar experiments
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123We developed a xenograft model of GIST characterized
by the deﬁnition and the maintenance of the molecular
target and by a good evaluation of tumor metabolism. This
model seems suitable for the development of new drugs or
combination of drugs for GIST treatment because it has
both the functional and molecular characterization. Imag-
ing studies with FDG provide information on glucose
metabolism associated with a standard measurement of
macroscopic size of the tumours. Moreover, considering
that TK inhibitors strongly reduce cell proliferation, a
radiotracer speciﬁcally targeting this biological effect as
FLT could also be used. FLT has already demonstrated to
be a tool for monitoring antiproliferative drugs in oncology
[7]. Both FDG and FLT tracers should be used for
assessing the biological markers for targeted therapies in
GISTs in the preclinical setting.
The strength of this ﬁrst consideration is markedly
underlined by clinical experiences. As well known, the
evaluation of tumor response to target therapies cannot be
based only on the change in size of lesions [8]. The tra-
ditional RECIST criteria that are still considered the
standard method for assessment of anticancer treatment
activity do not provide information on biological, vascular
or metabolic variations [9]. They should be associated with
other methods in order to detect modiﬁcations of the bio-
logical proﬁle of the tumour after therapy. Approximately
80% of patients affected by GISTs have a durable disease
response with TK inhibitors, but most of the time imatinib
does not lead to lesion shrinkage, on the contrary it may
induce intra-lesion functional or biological modiﬁcations.
The CHOI criteria using only contrasted-enhanced com-
puted tomography (CT) have been recently studied
evaluating both the tumour size and density variations after
imatinib [5, 6]. About functional imaging, the uptake of
FDG on PET may strongly decrease even 24 h after
imatinib or sunitinib administration and the decrement
correlates with the response [10]. Therefore, FDG-PET
alone showed a good potential for ‘‘early prediction’’ of the
tumour’s response, instead image fusion with combined
PET/CT contributes better to the response assessment to
TK inhibitors [11, 12]. In addition, FDG-PET may also
early identify foci of acquired resistance in tumours which
were initially responsive [13]. These clinical data suggest
that the use of preclinical imaging technologies for animal
models such as small animal PET, small animal CT, small
animal magnetic resonance may be considered mandatory
for the development of new therapeutic strategies in cancer
research [14–17]. The role of small animal PET is now
well recognized and the advantages of the acquisition of
in vivo imaging are already reported, such as faster eval-
uation of molecular pathway inhibition, and faster
information of prediction and assessment of the therapeutic
effect [14, 15]. At present, very few data have been pub-
lished on xenograft models of GIST especially for testing
the TK inhibitors activity using small animal PET [18, 19].
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Fig. 3 In vivo growth curve of GIST882 tumors. Negative animals
were not included in the curve. The arrow indicates the time when
PET analysis was performed
Fig. 2 Molecular KIT analysis
with a mutation in position
70040 of exon 13 (substitution
of a guanosine instead adenine).
a Normal genomic amino acids
KIT sequences. b Molecular
analysis of tumour of a
xenograft GIST882 mice after
sacriﬁce. c Molecular analysis
of cancer GIST882 cell line
before injection
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123Cullinane developed a mouse model with FDC-P1 cell
lines expressing two different KIT mutations that confer
responsiveness (V560G) and resistance (D816V) to imati-
nib. The reduction of FDG uptake, resulted as the reduction
of glucose transporter numbers at cell surface, was corre-
lated to tumour response, whereas no FDG uptake
modiﬁcations were correlated to tumour resistance [18].
Prenen also established a mouse model of GIST treated
with imatinib evaluated with small animal PET as a
promising model for comparing novel drugs or combined
treatments [19]. Again, the FDG uptake decrement 24 h
after imatinib treatments correlated to a tumour response.
As a future perspective, novel PET tracers for speciﬁ-
cally detecting other biological functions of tumour cells
such as KIT signalling or vascular endothelial growth factor
receptor (VEGFr) expression need to be studied more. Kil
and colleagues have recently synthesized a PET tracer
labelling imatinib with
11C that may be useful in monitoring
the drug response and assessing the drug resistance as well
[20]. That may be important for the clinical implications
especially because the possible acquisition of new muta-
tions during the natural course of metastatic disease, and in
addition to the possibility of a heterogeneity of resistance
mechanisms to TK inhibitors [21]. In addition, the PET
imaging of VEGFr may provide information on the effect of
sunitinib, even its anti-angiogenic activity in GIST is still
controversial [22]. However, even though the molecular
imaging perspectives seem promising, further in vivo
experimental studies are needed on these tracers.
The second consideration is that the development of
animal models with deﬁned molecular background may
also be considered in the preclinical setting as a modern
research approach. In fact, speciﬁc molecular mechanisms
has been demonstrated to predict the clinical response of
GISTs to the TK inhibitors [23, 24]. Although most of the
patients respond dramatically to imatinib, there is a small
subset that exhibits primary resistance mainly in case of
tumours with exon 9 mutant isoform protein and no
detectable mutation of KIT receptor [23]. Moreover, a
secondary drug resistance may also occur after a median of
Fig. 4 Small animal PET
images (lateral, coronal and
axial) of xenograft GIST882
mouse (GE, eXplore Vista DR
tomograph) at 88 days from
cells injection. FLT uptake
(top); FDG uptake (lower part)
Fig. 5 Pathological evaluation of GIST tumor after mouse sacriﬁce.
a Histological section stained with H&E. b KIT positive
immunohistochemistry
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123about 2 years, due to the acquisition of additional muta-
tions of KIT or PDGFR-alfa [25, 26]. Other single agents
or combined strategies are proposed to overcome the drug
resistance as third or fourth line of therapy. The preclinical
development of these new therapeutic strategies in GIST
requires advanced preclinical models. In fact, sophisticated
animal models of GIST have been developed. Recently,
knock-in murine animals by introducing a germ-line gain-
of-function mutation of KIT receptor into the mouse gen-
ome were described [27–31]. These models are considered
promising in order to investigate the role of the oncogenic
signalling pathways, to study the mechanism of drugs
resistance or response, or the study the up or down-regu-
lated molecular proﬁles drugs mediated and the acquisition
of secondary biological aberrations. Moreover, an high-
resolution analyses such as gene expression proﬁling or
whole genome genotyping could be considered in in vivo
experimental studies [32, 33]. The array-technologies have
the advantage to screen the global genome underlying to a
speciﬁc genotype. Finally, in the future the correlation
between imaging features and molecular analyses data may
permit to know the tumour molecular background in vivo
and globally with a non invasive approach which may be
potential for correctly choosing the anticancer treatments.
In conclusion, in the modern era of cancer research, the
GIST model suggests that the development of new thera-
peutic strategies requires a multi-expertise cooperation
between pathologists, oncologists, biologists, nuclear
medical doctors, radio-pharmacists, radiologists and
requires novel technologies for assessing better the effects
of putative drugs and for developing new treatments more
quickly. This approach on cancer research is crucial and
essential for innovative and exciting perspectives that
could cross over to other types of cancer.
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